Th9 cells promote antitumor immune responses in vivo
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Th9 cells are a subset of CD4+ Th cells that produce the pleiotropic cytokine IL-9. IL-9/Th9 can function as both positive and negative regulators of immune response, but the role of IL-9/Th9 in tumor immunity is unknown. We examined the role of IL-9/Th9 in a model of pulmonary melanoma in mice. Lack of IL-9 enhanced tumor growth, while tumor-specific Th9 cell treatment promoted stronger antitumor responses in both prophylactic and therapeutic models. Th9 cells also elicited strong host antitumor CD8+ CTL responses by promoting Ccl20/Ccr6-dependent recruitment of DCs to the tumor tissues. Subsequent tumor antigen delivery to the draining LN resulted in CD8+ T cell priming. In agreement with this model, Ccr6 deficiency abrogated the Th9 cell-mediated antitumor response. Our data suggest a distinct role for tumor-specific Th9 cells in provoking CD8+ CTL-mediated antitumor immunity and indicate that Th9 cell-based cancer immunotherapy may be a promising therapeutic approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“IL-9 has been shown to favour CD8 T-cell activation in a model of pulmonary melanoma in mice36.”
From Selective degradation of PU.1 during autophagy represses the differentiation and antitumour activity of TH9 cells (2017) · cites this paper as [36]
The cited source says what the claim attributes to it.
In the citing paper
“This observation is in contrast to previous findings demonstrating a role of Th9 cells in controlling anti-tumour immune responses in solid tumours such as melanomas.26,27”
From PU.1-driven Th9 Cells Promote Colorectal Cancer in Experimental Colitis Models Through Il-6 Effects in Intestinal Epithelial Cells (2022) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Veldhoen, M., Uyttenhove, C., van Snick, J., Helmby, H., Westendorf, A., Buer, J., Martin, B., Wilhelm, C., & Stockinger, B. (2008) · Nature Immunology · doi:10.1038/ni.1659 · Cited by 1,213
Dardalhon, V., Awasthi, A., Kwon, H., Galileos, G., Gao, W., Sobel, R. A., Mitsdoerffer, M., Strom, T. B., Elyaman, W., Ho, I.-C., et al. (2008) · Nature Immunology · doi:10.1038/ni.1677 · Cited by 1,122
Maldonado-López, R., De Smedt, T., Michel, P., Godfroid, J., Pajak, B., Heirman, C., Thielemans, K., Leo, O., Urbain, J., & Moser, M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.3.587 · Cited by 984
Tumor-specific Th17-polarized cells eradicate large established melanoma
Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 845
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090207 · Cited by 842
Self-citationT Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P., Restifo, N. P., Overwijk, W. W., & Dong, C. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.014 · Cited by 800
Helping the CD8+ T-cell response
Bevan, M. J. (2004) · Nature Reviews Immunology · doi:10.1038/nri1413 · Cited by 797
Jäger, A., Dardalhon, V., Sobel, R. A., Bettelli, E., & Kuchroo, V. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901906 · Cited by 783 · cited 3×
“Naive CD4 + CD62L + T cells purified from spleens of OT-II mice were differentiated into Th0, Th1, or Th9 cells according to established methods (32).”
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy
Knutson, K. L., & Disis, M. L. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0653-2 · Cited by 682
CCR6 Regulates the Migration of Inflammatory and Regulatory T Cells
Yamazaki, T., Yang, X. O., Chung, Y., Fukunaga, A., Nurieva, R., Pappu, B., Martin-Orozco, N., Kang, H. S., Ma, L., Panopoulos, A. D., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.12.8391 · Cited by 551
Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells
Turk, M. J., Guevara-Patiño, J. A., Rizzuto, G. A., Engelhorn, M. E., & Houghton, A. N. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041130 · Cited by 540
Elyaman, W., Bradshaw, E. M., Uyttenhove, C., Dardalhon, V., Awasthi, A., Imitola, J., Bettelli, E., Oukka, M., van Snick, J., Renauld, J.-C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812530106 · Cited by 498 · cited 1×
“Importantly, Tregs have been demonstrated to have Ccr6-dependent homing into tumor sites, and their function may be increased in the presence of IL-9 (26, 31).”
GeurtsvanKessel, C. H., Willart, M. A. M., van Rijt, L. S., Muskens, F., Kool, M., Baas, C., Thielemans, K., Bennett, C., Clausen, B. E., Hoogsteden, H. C., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071365 · Cited by 480
Th17 cells are long lived and retain a stem cell-like molecular signature
Muranski, P., Borman, Z. A., Kerkar, S. P., Klebanoff, C. A., Ji, Y., Sanchez-Perez, L., Sukumar, M., Reger, R. N., Yu, Z., Kern, S. J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.019 · Cited by 443
Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells
Purwar, R., Schlapbach, C., Xiao, S., Kang, H. S., Elyaman, W., Jiang, X., Jetten, A. M., Khoury, S. J., Fuhlbrigge, R. C., Kuchroo, V. K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2856 · Cited by 442
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Piconese, S., Valzasina, B., & Colombo, M. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071341 · Cited by 405
Goswami, R., & Kaplan, M. H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003049 · Cited by 399
IL-9 as a mediator of Th17-driven inflammatory disease
Nowak, E. C., Weaver, C. T., Turner, H., Begum-Haque, S., Becher, B., Schreiner, B., Coyle, A. J., Kasper, L. H., & Noelle, R. J. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090246 · Cited by 393
Interleukin‐4 and interleukin‐10 synergize to inhibit cell‐mediated immunity in vivo
Powrie, F., Menon, S., & Coffman, R. L. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230926 · Cited by 328
Schmitt, E., Germann, T., Goedert, S., Hoehn, P., Huels, C., Koelsch, S., Kühn, R., Müller, W., Palm, N., & Rüde, E. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.9.3989 · Cited by 299
Cellular sources and immune functions of interleukin-9
Noelle, R. J., & Nowak, E. C. (2010) · Nature Reviews Immunology · doi:10.1038/nri2848 · Cited by 298
Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment
Gajewski, T. F. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0892 · Cited by 230
Soroosh, P., & Doherty, T. A. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03114.x · Cited by 226
Quezada, S. A., Peggs, K. S., Simpson, T. R., Shen, Y., Littman, D. R., & Allison, J. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080099 · Cited by 218
Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients
Chen, X., Wan, J., Liu, J., Xie, W., Diao, X., Xu, J., Zhu, B., & Chen, Z. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.11.013 · Cited by 217
Self-citationThe critical role of Th1-dominant immunity in tumor immunology
Nishimura, T., Nakui, M., Sato, M., Iwakabe, K., Kitamura, H., Sekimoto, M., Ohta, A., Koda, T., & Nishimura, S. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/pl00014051 · Cited by 211
Eller, K., Wolf, D., Huber, J. M., Metz, M., Mayer, G., McKenzie, A. N. J., Maurer, M., Rosenkranz, A. R., & Wolf, A. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001183 · Cited by 182
Th17 cells in cancer: help or hindrance?
Wilke, C. M., Kryczek, I., Wei, S., Zhao, E., Wu, K., Wang, G., & Zou, W. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr019 · Cited by 180
Gessner, A., Blum, H., & Röllinghoff, M. (1993) · Immunobiology · doi:10.1016/s0171-2985(11)80414-6 · Cited by 164
Maintenance of the mouse type II cell phenotype in vitro
Rice, W. R., Conkright, J. J., Na, C.-L., Ikegami, M., Shannon, J. M., & Weaver, T. E. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00302.2001 · Cited by 157
Interleukin‐4 and interleukin‐10 synergize to inhibit cell‐mediated immunity in vivo
Powrie, F., Menon, S., & Coffman, R. L. (1993) · European Journal of Immunology · doi:10.1002/eji.1830231147 · Cited by 142
From interleukin‐9 to T helper 9 cells
Stassen, M., Schmitt, E., & Bopp, T. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06351.x · Cited by 141
Zhou, Y., Sonobe, Y., Akahori, T., Jin, S., Kawanokuchi, J., Noda, M., Iwakura, Y., Mizuno, T., & Suzumura, A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003307 · Cited by 138
Cytokines and effector T cell subsets causing autoimmune CNS disease
Petermann, F., & Korn, T. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.064 · Cited by 128
Munegowda, M. A., Deng, Y., Mulligan, S. J., & Xiang, J. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1054-y · Cited by 126
IL-9 and its Receptor: From Signal Transduction to Tumorigenesis
Knoops, L., & Renauld, J.-C. (2004) · Growth Factors · doi:10.1080/08977190410001720879 · Cited by 114
Gerloni, M., & Zanetti, M. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0193-z · Cited by 112
Tan, C., Aziz, M. K., Lovaas, J. D., Vistica, B. P., Shi, G., Wawrousek, E. F., & Gery, I. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001676 · Cited by 106
Li, H., Nourbakhsh, B., Cullimore, M. L., Zhang, G., & Rostami, A. M. (2011) · European Journal of Immunology · doi:10.1002/eji.201041125 · Cited by 103
Self-citationIL-9: Basic Biology, Signaling Pathways in CD4+ T Cells and Implications for Autoimmunity
Li, H., & Rostami, A. M. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9186-y · Cited by 86
Self-citationRegulating Il9 transcription in T helper cells
Perumal, N. B., & Kaplan, M. H. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.01.006 · Cited by 85
IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis
Wu, B., Huang, C., Kato‐Maeda, M., Hopewell, P. C., Daley, C. L., Krensky, A. M., & Clayberger, C. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.09.009 · Cited by 74
Kriegel, M. A., Rathinam, C., & Flavell, R. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115308109 · Cited by 67
Smith, S. E., Hoelzinger, D. B., Dominguez, A. L., Van Snick, J., & Lustgarten, J. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1075-6 · Cited by 67
IL‐9 is a Th17‐derived cytokine that limits pathogenic activity in organ‐specific autoimmune disease
Stephens, G. L., Swerdlow, B., Benjamin, E., Coyle, A. J., Humbles, A., Kolbeck, R., & Fung, M. (2011) · European Journal of Immunology · doi:10.1002/eji.201040879 · Cited by 56
Inflammatory Mediators Hold the Key to Dendritic Cell Suppression and Tumor Progression
Sheng, K., Wright, M. D., & Apostolopoulos, V. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711798347207 · Cited by 43
IL-9 Induces CCL11 Expression via STAT3 Signalling in Human Airway Smooth Muscle Cells
Yamasaki, A., Saleh, A. J., Koussih, L., Muro, S., Halayko, A. J., & GOUNNI, A. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009178 · Cited by 43
Cited by
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
The γc Family of Cytokines: Basic Biology to Therapeutic Ramifications
Leonard, W. J., Lin, J.-X., & O'Shea, J. J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.028 · Cited by 383
The development and in vivo function of T helper 9 cells
Kaplan, M. H., Hufford, M. M., & Olson, M. R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3824 · Cited by 384
Th9 cells: differentiation and disease
Kaplan, M. H. (2013) · Immunological Reviews · doi:10.1111/imr.12028 · Cited by 320
Chen, W. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-045939 · Cited by 280
Metadata
- Authors
- Lu, Y., Hong, S., Li, H., Park, J., Hong, B., Wang, L., Zheng, Y., Liu, Z., Xu, J., He, J., Yang, J., Qian, J., & Yi, Q.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Yi, Qing
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2012-10-15
- Volume
- 122
- Issue
- 11
- Pages
- 4160-4171
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3484462
- OpenAlex
- W2066906123
- Cited by
- 361
- References
- 50
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 19 · 2023: 25 · 2022: 27 · 2021: 24 · 2020: 33 · 2019: 37 · 2018: 35 · 2017: 34 · 2016: 34 · 2015: 26 · 2014: 18 · 2013: 13 · 2012: 1
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Multiple Myeloma Research Foundation
- Commonwealth Foundation
- Leukemia and Lymphoma Society
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (R01CA138402, R01CA138398, R01CA163881, P50CA142509, P30CA016672)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- Th9 cells, IL-9, antitumor immunity, pulmonary melanoma, CD8+ cytotoxic T lymphocytes, dendritic cell recruitment, tumor antigen delivery, draining lymph nodes, cancer immunotherapy, CD4+ T cells
- MeSH terms
- Animals, Dendritic Cells, T-Lymphocytes, Helper-Inducer, Immunity, Cellular, Immunotherapy, Lung Neoplasms, Melanoma, Interleukin-9, Antigen Presentation, Mice, Knockout, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Mice, Receptors, CCR6, Chemokine CCL20
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.